By efrat|2023-05-09T06:56:05+00:00May 9th, 2023|All|Comments Off on Dr. Oluwole Olalekan- Approval of Polatuzumab Vedotin Plus R-CHP in Previously Untreated DLBCL
By efrat|2023-05-02T06:45:05+00:00May 2nd, 2023|All|Comments Off on Dr. Bhagirathbhai Dholaria- Omisirge Allogeneic Cord Blood-Based Cell Therapy Approved to Reduce Risk of Infection Following Stem Cell Transplantation
By efrat|2023-04-23T12:10:58+00:00April 23rd, 2023|All|Comments Off on Dr. Paula Rodríguez Otero- Ide-cel or Standard Regimens in Relapsed and Refractory Multiple Myeloma
By efrat|2023-04-03T16:12:03+00:00April 3rd, 2023|All|Comments Off on Prof. Christoph Stein Thoeringer- Role of the Gut Microbiome in CAR-T cell Therapy
By efrat|2023-01-22T07:12:06+00:00January 22nd, 2023|All|Comments Off on Dr. Doris Hansen- Idecabtagene Vicleucel for Relapsed/Refractory Multiple Myeloma: Real-World Experience From the Myeloma CAR T Consortium
By efrat|2022-11-11T07:58:01+00:00November 11th, 2022|All|Comments Off on Prof. Marion Subklewe- T-cell exhaustion induced by continuous bispecific molecule exposure
By efrat|2022-11-07T09:58:15+00:00November 7th, 2022|All|Comments Off on Prof. Mohamad Mohty – FDA Breakthrough Therapy Designation for Elranatamab in Relapsed or Refractory Multiple Myeloma
By efrat|2022-10-24T08:28:01+00:00October 24th, 2022|All|Comments Off on Dr. Eolia Brissot – Positive opinion of the CHMP on tabelecleucel for the treatment of Epstein-Barr Virus-Positive Post-Transplant Lymphoproliferative Disease
By Amnon Ron|2022-10-17T08:48:06+00:00October 17th, 2022|All|Comments Off on Prof. Mohamed Kharfan Dabaja – Positive Results from Final Progression-Free Survival Analysis of zanubrutinib Compared to ibrutinib in CLL
